share_log

bluebird bio | 8-K: Current report

bluebird bio | 8-K: Current report

bluebird bio | 8-K:重大事件
美股SEC公告 ·  2024/10/04 15:10

Moomoo AI 已提取核心信息

bluebird bio received a notice from Nasdaq on September 30, 2024, indicating non-compliance with the minimum bid price requirement of $1.00 per share, as its stock has traded below this threshold for 32 consecutive business days. The company has been granted a 180-day grace period until March 31, 2025, to regain compliance by maintaining a closing bid price of at least $1.00 for 10 consecutive business days.If unable to meet the requirement by March 31, 2025, the company may be eligible for an additional 180-day compliance period by transferring to the Nasdaq Capital Market. bluebird bio is actively monitoring its stock price and considering various options, including seeking shareholder approval for a reverse stock split at its 2024 Annual Meeting. The notice has no immediate effect on the company's listing, which continues to trade under "BLUE" on the Nasdaq Global Select Market.
bluebird bio received a notice from Nasdaq on September 30, 2024, indicating non-compliance with the minimum bid price requirement of $1.00 per share, as its stock has traded below this threshold for 32 consecutive business days. The company has been granted a 180-day grace period until March 31, 2025, to regain compliance by maintaining a closing bid price of at least $1.00 for 10 consecutive business days.If unable to meet the requirement by March 31, 2025, the company may be eligible for an additional 180-day compliance period by transferring to the Nasdaq Capital Market. bluebird bio is actively monitoring its stock price and considering various options, including seeking shareholder approval for a reverse stock split at its 2024 Annual Meeting. The notice has no immediate effect on the company's listing, which continues to trade under "BLUE" on the Nasdaq Global Select Market.
bluebird bio于2024年9月30日收到了纳斯达克的通知,指出其未能符合每股最低买盘价格1.00美元的要求,因为其股票连续32个交易日低于这一门槛。公司获准有180天的宽限期,直到2025年3月31日,在此期间需保持至少10个连续交易日的收盘买盘价格至少为1.00美元以恢复合规。如果未能在2025年3月31日前满足该要求,企业可以通过转到纳斯达克资本市场获得额外的180天合规期。bluebird bio正在积极监测其股价,并考虑各种期权,包括在2024年年度会议上寻求股东对反向拆分股票的批准。该通知对公司的上市没有立即影响,公司股票仍在纳斯达克全球精选市场以“BLUE”交易。
bluebird bio于2024年9月30日收到了纳斯达克的通知,指出其未能符合每股最低买盘价格1.00美元的要求,因为其股票连续32个交易日低于这一门槛。公司获准有180天的宽限期,直到2025年3月31日,在此期间需保持至少10个连续交易日的收盘买盘价格至少为1.00美元以恢复合规。如果未能在2025年3月31日前满足该要求,企业可以通过转到纳斯达克资本市场获得额外的180天合规期。bluebird bio正在积极监测其股价,并考虑各种期权,包括在2024年年度会议上寻求股东对反向拆分股票的批准。该通知对公司的上市没有立即影响,公司股票仍在纳斯达克全球精选市场以“BLUE”交易。
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息